Antimicrobial peptides in nasal secretion and mucosa with respect to S. aureus colonisation in Wegener's granulomatosis

Clinical and Experimental Rheumatology

Volumn 29, Issue 1 SUPPL. 64, 2011, Pages

  Hui, Y ^a   Wohlers, J ^b   Podschun, R ^c   Hedderich, J ^c   Lamprecht, P ^d   Ambrosch, P ^b   Laudien, Martin ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Antimicrobial peptides; hBD 3; LL 37; Staphylococcus aureus; Wegener's granulomatosis

Indexed keywords

ANTIBIOTIC AGENT; ANTIMICROBIAL PEPTIDE HBD 3; AZATHIOPRINE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CYCLOPHOSPHAMIDE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; POLYPEPTIDE ANTIBIOTIC AGENT; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; BETA DEFENSIN 3;

ADULT; ARTICLE; BACTERIAL COLONIZATION; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NOSE MUCOSA; NOSE SECRETION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS; SUPERNATANT; WEGENER GRANULOMATOSIS; NONHUMAN;

ADULT; BETA-DEFENSINS; BODILY SECRETIONS; CARRIER STATE; CASE-CONTROL STUDIES; CATHELICIDINS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASAL MUCOSA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; WEGENER GRANULOMATOSIS;

EID: 79960413162     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. PHILLIP R, LUQMANI R: Mortality in systemic vasculitis: a systematic review. Clin Exp Rheumatol 2008; 26 (Suppl. 51): S94-104.
2. LAUDIEN M, AMBROSCH P, TILL A, PODSCHUN R, LAMPRECHT P: Diagnosis, therapy and current research aspects of selected chronic inflammatory diseases with head and neck involvement. Z Rheumatol 2008; 67: 397-406.
3. AVCIN T, CANOVA M, GUILPAIN P et al.: Infections, connective tissue diseases and vasculitis. Clin Exp Rheumatol 2008; 26 (Suppl. 48): S18-S26.
4. CHEN M, KALLENBERG CG: New advances in the pathogenesis of ANCA-associated vasculitides. Clin Exp Rheumatol 2009; 27 (Suppl. 52): S108-S114.
5. HAMIDOU MA, AUDRAIN M, NININ E, ROBILLARD N, MULLER JY, BONNEVILLE M: Staphylococcus aureus, T-cell repertoire, and Wegener's granulomatosis. Joint Bone Spine 2001; 68: 373-7.
6. HOFFMAN GS, KERR GS, LEAVITT RY et al.: Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116: 488-98.
7. REINHOLD-KELLER E, BEUGE N, LATZA U et al.: An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000; 43: 1021-32.
8. BACON PA: The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352: 330-2.
9. STEGEMAN CA, TERVAERT JW, SLUITER WJ, MANSON WL, DE JONG PE, KALLENBERG CG: Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120: 12-7.
10. STEGEMAN CA, TERVAERT JW, DE JONG PE, KALLENBERG CG: Trimethoprim- sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. DUTCH CO-TRIMOXAZOLE WEGENER STUDY GROUP. N Engl J Med 1996; 335: 16-20.
11. JAGIELLO P, GROSS WL, EPPLEN JT: Complex genetics of Wegener granulomatosis. Autoimmun Rev 2005; 4: 42-7.
12. POPA ER, STEGEMAN CA, ABDULAHAD WH et al. Staphylococcal toxic-shock-syndrometoxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46: 1029-33.
13. SWIDSINSKI A, LADHOFF A, PERNTHALER A et al.: Mucosal flora in inflammatory bowel disease. Gastroenerology 2002; 122: 44-54.
14. BALS R: Epithelial antimicrobial peptides in host defense against infection. Respir Res 2000; 1: 141-50.
15. LAUDIEN M, GADOLA S, PODSCHUN R et al.: Nasal carriage of Staphylococcus aureus and endonasal activity in Wegener's granulomatosis as compared to rheumatoid arthritis and chronic Rhinosinusitis with nasal polyps. Cini Exp Rheumatol accepted 2010.
16. ULLRICH S, GUSTKE H, LAMPRECHT P et al.: Severe impaired respiratory ciliary function in Wegener granulomatosis. Ann Rheum Dis 2009; 68: 1067-71.
17. GANZ T: Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 3: 710-20.
18. DE SMET K, CONTRERAS R: Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27: 1337-47.
19. BALS R, WANG X, ZASLOFF M, WILSON JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998; 95: 9541-6.
20. GARCIA JR, JAUMANN F, SCHULZ S et al.: Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res 2001; 306: 257-64.
21. HARDER J, BARTELS J, CHRISTOPHERS E, SCHRODER JM: Isolation and characterisation of human beta -defensin-3, a novel human inducible peptide antibiotic. J Biol Chem 2001; 276: 5707-13.
22. NIJNIK A, HANCOCK RE: The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009; 16: 41-7.
23. HATA TR, GALLO RL: Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg 2008; 27: 144-50.
24. DUITS LA, RADEMAKER M, RAVENSBERGEN B et al.: Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids. Biochem Biophys Res Commun 2001; 280: 522-5.
25. CHEN PH, FANG SY: The expression of human antimicrobial peptide LL-37 in the human nasal mucosa. Am J Rhinol 2004; 18: 381-5.
26. KIM ST, CHA HE, KIM DY, HAN GC, CHUNG YS, LEE YJ et al. Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 2003; 123: 81-5.
27. NELL MJ, TJABRINGA GS, VONK MJ, HIEMSTRA PS, GROTE JJ: Bacterial products increase expression of the human cathelicidin hCAP-18/LL-37 in cultured human sinus epithelial cells. FEMS Immunol Med Microbiol 2004; 42: 225-31.
28. OOI EH, WORMALD PJ, CARNEY AS, JAMES CL, TAN LW: Fungal allergens induce cathelicidin LL-37 expression in chronic rhinosinusitis patients in a nasal expiant model. Am J Rhinol 2007; 21: 367-72.
29. OOI EH, WORMALD PJ, TAN LW: Innate immunity in the paranasal sinuses: a review of nasal host defenses. Am J Rhinol 2008; 22: 13-9.
30. OOI EH, WORMALD PJ, CARNEY AS, JAMES CL, TAN LW: Human cathelicidin antimicrobial peptide is up-regulated in the eosinophilic mucus subgroup of chronic rhinosinusitis patients. Am J Rhinol 2007; 21: 395-401.
31. HELLMICH B, FLOSSMANN O, GROSS WL et al.: EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007; 66: 605-17.
32. LUQMANI RA: Assessing disease activity in the systemic vasculitides. Curr Opin Rheumatol 2002; 14: 23-8.
33. DE REMEE RA, MCDONALD TJ, HARRISON EG JR, COLES DT: Wegener's granulomatosis. Anatomic correlates, a proposed classification. Mayo Clin Proc 1976; 51: 777-81.
34. PAULSEN JI, RUDERT H: (Manifestations of primary vasculitis in the ENT region). Z Rheumatol 2001; 60: 219-25.
35. HOLTFRETER S, GRUMANN D, SCHMUDDE M et al.: Clonal distribution of superantigen genes in clinical Staphylococcus aureus isolates. J Clin Microbiol 2007; 45: 2669-80.
36. BALL SL, SIOU GP, WILSON JA, HOWARD A, HIRST BH, HALL J: Expression and immunolocalisation of antimicrobial peptides within human palatine tonsils. J Laryngol Otol 2007; 121: 973-8.
37. LYSENKO ES, GOULD J, BALS R, WILSON JM, WEISER JN: Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the up- . per respiratory tract. Infect Immun 2000; 68: 1664-71.
38. TJABRINGA GS, VOS JB, OLTHUIS D et at: Host defense effector molecules in mucosal secretions. FEMS Immunol Med Microbiol 2005; 45: 151-8.
39. CLAEYS S, DE BELDER T, HOLTAPPELS G et al.: Human beta-defensins and toll-like receptors in the upper airway. Allergy 2003; 58: 748-53.
40. LAUBE DM, YIM S, RYAN LK, KISICH KO, DIAMOND G: Antimicrobial peptides in the airway. Curr Top Microbiol Immunol 2006; 306: 153-82.
41. QUINN GA, COLE AM: Suppression of innate immunity by a nasal carriage strain of Staphylococcus aureus increases its colonisation on nasal epithelium. Immunology 2007; 122: 80-9.
42. SAHLY H, SCHUBERT S, HARDER J et al.: Burkholderia is highly resistant to human Beta-defensin 3. Antimicrob Agents Chemother 2003; 47: 1739-41.
43. OTTO M: Bacterial sensing of antimicrobial peptides. Contrib Microbiol 2009; 16: 136-49.
44. SIEPRAWSKA-LUPA M, MYDEL P, KRAWCZYK K et al.: Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob Agents Chemother 2004; 48: 4673-9.
45. GLASER R, MEYER-HOFFERT U, HARDER J et al: The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption. J Invest Dermatol 2009; 129: 641-9.
46. CHEN X, NIYONSABA F, USHIO H et al.: Synergistic effect of antibacterial agents human beta-defensins, cathelicidin LL-37 and lysozyme against Staphylococcus aureus and Escherichia coli. J Dermatol Sci 2005; 40: 123-32.
47. HARDER J, GLASER R, SCHRODER JM: The role and potential therapeutical applications of antimicrobial proteins in infectious and inflammatory diseases. Endocr Metab Immune Disord Drug Targets 2007; 7: 75-82.